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Abstract
Introduction: To report a case of ofloxacin-associated leucopoenia, which occurred in a patient of
falciparum malaria shortly after administration and resolved following discontinuation of the drug.
Case presentation: A 44 year old female was admitted in circulatory shock with a diagnosis of
falciparum malaria, suffering from fever, diarrhoea and vomiting. After successful resuscitation she
was treated with intravenous ofloxacin for Escherichia coli induced diarrhoea. She developed acute
leucopoenia that resolved after discontinuation of the drug.
Discussion: Ofloxacin is a broad-spectrum synthetic fluoroquinolone used for a wide variety of
bacterial infections. Because of the temporal relationship between ofloxacin administration and the
development of leucopenia in our patient, as well as the relationship between drug withdrawal and
improvement in white blood cell count, ofloxacin-associated leucopenia was suspected. This reaction
was categorized as probable according to the Naranjo probability scale. We report, for the first time
in the English-language literature, a case of Ofloxacin-associated leucopoenia. This association is
further supported by the exclusion of other potential causes for this adverse effect.
Conclusion: Leucopoenia is a well-recognized adverse effect of several drugs. We report a case of
Ofloxacin-associated leucopoenia during treatment of a patient with malaria. Healthcare personnel
should be aware of this possible adverse reaction in patients treated with ofloxacin. A high degree of
suspicion assumes special importance in this subgroup of critically ill patients with malaria where
hematologic aberrations are common.
Introduction
Drug induced leucopenia may complicate any clinical
situation. We present a case of probable ofloxacin induced
leucopenia in a patient with falciparum malaria where the
condition reverted to normal promptly after stopping the
drug. Cases of coexisting malaria and pancytopenia are not
u n k n o w ni na r e a sw i t hah i g hp revalence of complicated
falciparum malaria. A dilemma of deciding whether the
leucopeniainacaseoffalciparummalariaisduetothedisease
process or an adverse drug reaction may arise at such times.
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A 44-year Asian-Indian female presented with fever, diar-
rhoeaandvomitingoffivedaysduration.Shewasdiagnosed
to have Plasmodium falciparum malaria elsewhere by immu-
nochromatographic test. Prior treatment received was
parenteral artesunate for three days. A worsening clinical
status necessitated referralto our institute for management.
At presentation, the patient was in circulatory shock - heart
rate 160/min, blood pressure 80/50mmHg. She was
resuscitated with intravenous fluids and inotropic agents.
Biochemical examination showed raised serum urea
(58 mg/dl), creatinine (2.1 mg/dl), liver enzymes and
normal electrolytes(Sodium 138 meq/dl, Potassium
4.2 meq/dl). Hematological parameters included normal
leukocytecounts(8.6× 109/l),mildanemia(Hemoglobin-
9.2 g/dl) and thrombocytopenia (platelets-150 × 109/l)
(Table 1). Bleeding and clotting times were normal. Chest
xr a yw a sn o r m a l .
Over the next two days signs of clinical deterioration
suggestive of acute renal failure were noted. The patient
continued to have severe diarrhoea. Alterations in haema-
tological parameters showed worsening anemia (Hemo-
globin -8 g/dl) and thrombocytopenia (50 × 109/l). Total
leucocyte counts were stable (8.2 × 109/l). At this stage
stool culture grew colonies of Escherichia coli which were
sensitive to ofloxacin and carbapenem. The patient was
started on intravenous ofloxacin (200 mg twice a day) after
adjusting for impaired renal function.
After five days of treatment patient continued to deterio-
rate. She showed persistent oozing from site of puncture.
Altered hematological profile included a drop in platelet
counts, hemoglobin and packed cell volume. Severe
leucopenia (1.6 × 109/l) was noted.
Peripheral blood smear and quantitative buffy coat test for
malaria parasite were negative. Erythrocyte sedimentation
rate was 45, 55 and 50 mm in first hour and C reactive
protein of 65, 68 and 61 mg/dl on first, fourth and sixth
days respectively. Chest X ray did not show any evidence of
new infection. Ultrasonography of abdomen and pelvis
was normal. Microbiological cultures form blood, tracheal
secretions and urine failed to show any growth. Serial tests
of sputum were negative for acid fast bacilli. Widal test was
non reactive. On day six, hematologic profile continued to
deteriorate (Table1).
Drug induced leucopenia was the provisional diagnosis.
The patient was on injection ofloxacin, artesunate, pre and
probiotics for diarrhoea, rabeprazole, salbutamol and
dopamine infusion. Ofloxacin was discontinued at this
stage.
Hematological profile showed signs of stabilization on
day seven. The cell counts started improving (Table 1) and
reached near normal levels by day ten of treatment. The
patient had received no blood or component transfusion
in the interim. Bone marrow done on day eight showed
hypercellularity and signs of regeneration (Figure 1). Bone
marrow differential counts revealed an increased promye-
locye (26%) and myelocyte count (18%). (Table 2)
She developed late-onset ventilator associated pneumonia
by 18
th day and was put on Carbapenem therapy. She
stabilized with residual renal compromise requiring
haemodialysis and was discharged after one month with
complete recovery.
Discussion
Leucopenia in a critically ill patient can be attributed to
various causes. Falciparum malaria is associated with
anemia and thrombocytopenia due to hemophagocytosis
and hemolysis. Leucopenia and pancytopenia are less
common [1-3]. Lathia and colleagues have shown
that thrombocytopenia alone (platelet count less than
150,000 mm
-3) was a predictor for malaria and in
combination with anemia (Hb < 10 g/dl) it was next
best parameter. RDW and leukocyte count were not
Table 1. Blood counts during the course of illness
DAY Haemoglobin (g/dl) TLC (× 10
9/l) DC (%) Platelets (× 10
9/l) Reticulocyte (%)
Ofloxacin started on DAY 3
Day 1 9.2 8.6 N57, E3, L39 150 0.3
DAY 3 10.0 8.2 N73, E2, L24 50 0.1
DAY 4 8.5 7.0 N72, E1, L25 50 0.1
DAY 5 7.3 1.6 N32, E6 L62 40
Ofloxacin stopped on DAY 6
DAY 6 10.2 1.5 N22, E6, L72 28
DAY 7 10.3 2.7 N35, E2, L49 54
DAY 9 9.6 10.0 N38, MMC2, MC9 81 5
Day 10 10.0 15.0 MC15MC+St6, E1, L32 150 6
Abbreviations: TLC: total leucocyte count; DC: differential count; N: neutrophils; E: eosinophils; L: lymphocytes; M: monocytes; MC: myelocytes; MMC:
metamyelocyte; St: stab form.
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antimalarial treatment and had no evidence for presence
of parasites at the time of the episode of sudden
leucopenia.
Other infections (tuberculosis, salmonellosis etc), sepsis
and connective tissue diseases can cause macrophage
activation syndrome [5] and leucopenia. Repeated smears
showed absolute pancytopenia with no evidence of
premature cells or hemolysis. Bone marrow biopsy did
not reveal hemophagocytosis; splenomegaly was not
documented. There was no evidence of severe sepsis in
our patient in the form of rising CRP levels, or positive
microbial cultures.
Drug-induced leukopenias can occur in a dose-dependent
relationship or in an idiosyncratic, dose-independent
hypersensitivity reaction. The antimalarial drug artesunate
has proven to be very safe and the only incidents of
hematologic adverse effects associated with it occur when it
is used in combination therapy [6] - with amodiaquine an
agent known to cause leucopenia [7]. None of the other
drugs being administered to our patient are known to cause
this adverse effect. No drug other than Ofloxacin was
discontinued prior to the rapid improvement in leucocyte
counts.
Ofloxacin is a commonly used fluoroquinolone agent in
gastrointestinal infections and been associated with
adverse effects such as seizures, hypersensitivity vasculitis,
hemoglobinurea etc [8,9].
Other drugs of this group have been implicated in serious
hematologic adverse effects. Search of literature led us to
similar cases where ciprofloxacin, levofloxacin, trovaflox-
acin and moxifloxacin were implicated as the cause of
neutropenia, pancytopenia or bone marrow suppression
[10-13]. The exact mechanism of action of these reactions
are not well known till date. Having been administered for
two days in a modified dose, serum level was not
investigated. Re-challenge with the drug was not done
due to ethical reasons.
The temporal sequence of events implicates ofloxacin as
a probable cause of bone marrow suppression Naranjo
probability scale score 6 [14] which exacerbated the pre-
existing anaemia and thrombocytopenia. An idiosyncratic
reaction cannot be ruled out.
Conclusion
Leucopenia in falciparum malaria is less common than
anemia and thrombocytopenia.
Table 2. Bone marrow differential counts on eighth day
Differential (%)
Cell type Case Normal range (%)
Myeloblast 2 0.3-5.0
Promyelocyte 26 1-8
Myelocyte 18 8-16
Metamyelocyte + stab form 4 18-40
Segmented neutrophill 30 3-11
Eosinophil 1 1-5
Normoblast 18 18-36
Lymphocyte 17 11-23
Mononcyte 1 0-0.8
Plasma cell 1 0.4-3.9
Myeloid:erythroid ratio 1.1 1.5-3.3
Figure 1. Bone marrow aspirate showing maturation arrest
in the WBC series and erythroid hyperplasia. (leishman
stain, ×100).
Figure 2. Bone marrow aspirate showing a marrow particle
which is hypercellular. (leishman stain, ×10).
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related.
 Ofloxacin may cause leucopenia as reported for other
Quinolones.
 Suspected/most relevant drug possibly causing the
leucopenia should be promptly stopped.
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